UPTAKE OF BIOSIMILAR INFLIXIMAB: BUDGET SAVINGS OR MARKET EXPANSION ACROSS COUNTRIES?

被引：0
|
作者：
Kim, Y. [1 ]
Kwon, H. Y. [2 ]
Godman, B. [3 ]
Moorkens, E. [4 ]
Simoens, S. [4 ]
Bae, S. [1 ]
机构：
[1] Ewha Womans Univ, Coll Pharm, Seoul, South Korea
[2] Mokwon Univ, Seoul, South Korea
[3] Univ Strathclyde, Strathclyde Inst Pharm & Biomed Sci, Glasgow, Lanark, Scotland
[4] Katholieke Univ Leuven, Leuven, Belgium
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PBI45
引用
收藏
页码：S425 / S425
页数：1
相关论文
共 50 条
  • [1] Uptake of Biosimilar Infliximab in the UK, France, Japan, and Korea: Budget Savings or Market Expansion Across Countries?
    Kim, Yujeong
    Kwon, Hye-Young
    Godman, Brian
    Moorkens, Evelien
    Simoens, Steven
    Bae, SeungJin
    FRONTIERS IN PHARMACOLOGY, 2020, 11
  • [2] INFLIXIMAB MARKET SHARE AND ASSOCIATED COST SAVINGS FOLLOWING BIOSIMILAR MARKET ENTRY
    Paglinco, Samantha
    Abdel-Rasoul, Mahmoud
    Mcnicol, Megan
    Boyle, Brendan
    Dotson, Jennifer
    Michel, Hilary
    Maltz, Ross
    INFLAMMATORY BOWEL DISEASES, 2024, 30 : S51 - S51
  • [3] The Budget Impact of Biosimilar Infliximab (Remsima®) for the Treatment of Autoimmune Diseases in Five European Countries
    Ashok Jha
    Alex Upton
    William C. N. Dunlop
    Ron Akehurst
    Advances in Therapy, 2015, 32 : 742 - 756
  • [4] The Budget Impact of Biosimilar Infliximab (RemsimaA®) for the Treatment of Autoimmune Diseases in Five European Countries
    Jha, Ashok
    Upton, Alex
    Dunlop, William C. N.
    Akehurst, Ron
    ADVANCES IN THERAPY, 2015, 32 (08) : 742 - 756
  • [5] MARKET POTENTIAL OF A NEW INFLIXIMAB BIOSIMILAR IN THE EUROPEAN MARKET: A BUDGET IMPACT ANALYSIS IN FRANCE, ITALY AND THE UK
    Psachoulia, E.
    Martin-Rinconada, M. C.
    Bresson, A.
    Negrini, C.
    Keady, S.
    VALUE IN HEALTH, 2016, 19 (07) : A457 - A457
  • [6] BUDGET IMPACT ANALYSIS OF BIOSIMILAR INFLIXIMAB TREATMENT FOR RHEUMATOID ARTHRITIS IN SIX CENTRAL EUROPEAN COUNTRIES
    Brodszky, V
    Pentek, M.
    Baji, P.
    Balogh, O.
    Hever N, V.
    Gulacsi, L.
    VALUE IN HEALTH, 2013, 16 (07) : A558 - A558
  • [7] Is the Availability of Biosimilar Adalimumab Associated with Budget Savings? A Difference-in-Difference Analysis of 14 Countries
    Hyunjung Woo
    Gyeongseon Shin
    Donghwan Lee
    Hye-Young Kwon
    SeungJin Bae
    BioDrugs, 2024, 38 : 133 - 144
  • [8] Is the Availability of Biosimilar Adalimumab Associated with Budget Savings? A Difference-in-Difference Analysis of 14 Countries
    Woo, Hyunjung
    Shin, Gyeongseon
    Lee, Donghwan
    Kwon, Hye-Young
    Bae, Seungjin
    BIODRUGS, 2024, 38 (01) : 133 - 144
  • [9] Budget impact analysis of infliximab biosimilar: the Italian scenery
    Lucioni, Carlo
    Mazzi, Silvio
    Caporali, Roberto
    GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT, 2015, 2 (02) : 78 - 88
  • [10] BUDGET IMPACT ANALYSIS OF INTRODUCING BIOSIMILAR INFLIXIMAB FOR THE TREATMENT OF AUTO IMMUNE DISORDERS IN FIVE EUROPEAN COUNTRIES
    Jha, A.
    Upton, A.
    Dunlop, W.
    VALUE IN HEALTH, 2014, 17 (07) : A525 - A525
12345